There is such a company that started in a small county in Shanxi six years ago. From the initial sales of 500,000 yuan to the present company’s annual sales of more than 50 million yuan, biological antibody products are exported to the United States, Britain, Germany, South Korea, Japan, and Ireland. In developed countries, it was the first Chinese company that invented droplets to generate oil, and the first company to successfully synthesize an amylase substrate to break the monopoly of Roche. This company engaged in the research and development and production of the core raw materials of in vitro diagnostic reagents is called Ruiyali Group. The head of the company is Su Shaobo, a senior engineer from Shenzhen Advanced Institute.

By introducing the current status and pain points of the in vitro diagnostic reagent raw material industry in China, it analyzes and thinks about the current status of the in vitro diagnostic reagent market, and points out the future industry development direction and looks forward to the future.

On May 24, 2020, the State Council approved the integration and optimization of Guangdong Shenzhen Export Processing Zone into Shenzhen Pingshan Comprehensive Bonded Zone. According to the relevant requirements of the "Letter of the General Administration of Customs on the Planning and Construction of Shenzhen Pingshan Comprehensive Bonded Zone" (Shou Maohan [2020] No. 154), Shenzhen Pingshan Comprehensive Bonded Zone shall apply to the General Administration of Customs for acceptance within one year from the date of approval of the establishment of the State Council .

"Three International Centers" were unveiled, and Shenzhen Pingshan Comprehensive Bonded Zone officially passed customs clearance and acceptance!